Board of Directors have approved Audited Financial Results for Quarter and Year ending 31st March,2025 in Board Meeting held.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Drugs' board approved audited standalone and consolidated results for FY25 on 23rd May 2025. Standalone revenue declined to Rs 3,693.21 lakhs from Rs 4,326.07 lakhs in FY24 (down ~14.6%). Standalone profit after tax fell to Rs 29.57 lakhs from Rs 41.94 lakhs (down ~29.5%), though profit before tax improved slightly to Rs 64.13 lakhs from Rs 55.84 lakhs. Consolidated revenue was nearly flat at Rs 4,524.46 lakhs, while consolidated PAT dropped to Rs 33.62 lakhs from Rs 47.24 lakhs. Auditor (M/s. Pundarikashyam and Associates) issued an unmodified opinion but flagged emphasis of matters regarding Rs 4.14 Crores in long-pending trade receivables (over 2 years old) with no bad-debt provision, unreconciled balances awaiting party confirmation, and closing stocks accepted on management representation. Operating cash flow remained positive at Rs 316.31 lakhs standalone.
Weak headline earnings with declining standalone revenue and sharply lower PAT may pressure the stock. The auditor's emphasis on aged unpaid receivables with no provision is a credit-quality concern that investors should watch, despite the clean audit opinion.